Global Medical Affairs, bioMérieux, Marcy L'Etoile, France.
Clinical Investigation Center CIC1435, Inserm, CHU Limoges, Limoges, France.
J Antimicrob Chemother. 2024 Sep 19;79(Supplement_1):i26-i31. doi: 10.1093/jac/dkae280.
Bloodstream infections are linked to heightened morbidity and mortality rates. The consequences of delayed antibiotic treatment can be detrimental. Effective management of bacteraemia hinges on rapid antimicrobial susceptibility testing.
This retrospective study examined the influence of the VITEK® REVEAL™ Rapid AST system on positive blood culture (PBC) management in a French tertiary hospital.
Between November 2021 and March 2022, 79 Gram-negative monomicrobial PBC cases underwent testing with both VITEK®REVEAL™ and VITEK®2 systems.
The study found that VITEK®REVEAL™ yielded better results than the standard of care, significantly shortening the time to result (7.0 h compared to 9.6 h) as well as the turnaround time (15 h compared to 31.1 h) when applied for all isolates.
This study implies that the use of VITEK®REVEAL™ enables swift adaptations of antibiotic treatment strategies. By considerably minimizing the turnaround time, healthcare professionals can promptly make necessary adjustments to therapeutic regimens. Notably, these findings underscore the potential of VITEK®REVEAL™ in expediting appropriate antibiotic interventions, even in less ideal conditions. Further studies in varied laboratory contexts are required to validate these encouraging outcomes.
血流感染与更高的发病率和死亡率有关。延迟抗生素治疗的后果可能是有害的。有效的菌血症管理取决于快速的抗菌药物敏感性测试。
本回顾性研究调查了 VITEK®REVEAL™快速 AST 系统对法国一家三级医院阳性血培养（PBC）管理的影响。
在 2021 年 11 月至 2022 年 3 月期间，79 例革兰氏阴性单一致病菌血培养病例同时接受了 VITEK®REVEAL™和 VITEK®2 系统的检测。
研究发现，与标准护理相比，VITEK®REVEAL™ 产生了更好的结果，显著缩短了结果时间（所有分离物的 7.0 小时与 9.6 小时相比）和周转时间（15 小时与 31.1 小时相比）。
本研究表明，VITEK®REVEAL™ 的使用能够迅速调整抗生素治疗策略。通过大大缩短周转时间，医疗保健专业人员可以迅速对治疗方案进行必要的调整。值得注意的是，这些发现强调了 VITEK®REVEAL™ 在加快适当抗生素干预方面的潜力，即使在不太理想的条件下也是如此。需要在不同的实验室环境中进行进一步的研究来验证这些令人鼓舞的结果。
